NCT00663338View on ClinicalTrials.gov

Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions
Right Hemisphere StrokeHemispatial NeglectMotor Deficit
Interventions
DRUG

Rotigotine

Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.

Trial Locations (3)

E9 6SR

Homerton University Hospital, London

W68RF

Charing Cross Hospital, London

WC1N 3BG

The National Hospital for Neurology & Neurosurgery, London

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

University College, London

OTHER

NCT00663338 - Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke | Biotech Hunter | Biotech Hunter